Patent ID: 7309706

Claim:
A method of treating a clinical bone condition involving an undesirable amount of bone resorption selected from the group consisting of osteoporosis, hypercalcaemia, osteopenia, Paget's disease and osteopathies caused by glucocorticoid, steroid or corticosteroid therapy or by a sex hormone deficiency in a human or larger mammal in need thereof, said method comprising administering to said human or larger mammal a pharmaceutically effective amount of a selective imidazoline receptor agonist selected from the group consisting of moxonidine, rilmenidine, cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine, 5-[(2-bromophenoxy)methyl]-4,5-dihydro-oxazol-2-ylamine, 1-(2,4-dichlorobenzyl)-2-(4,5-dihydro-1H-imidazol-2-yl)-4-methylpiperazine, 1,2-diisopropyl-2-(4,5-dihydro-1H-imidazol-2-yl)-piperazine, and 1-(4,5-dihydro-1H-imidazol-2-yl)-isoquinoline or a physiologically compatible salt thereof, whereby Na+-independent chloride-bicarbonate exchanger proteins are reduced.